Here, we demonstrate that neither of the HCC tissues, responder and non-responder to galunisertib effectiveness in vitro according to our previous investigation,15 contained the somatic mutations most frequently found in HCCs, such as TERT or TP53 mutations.21 This evidence concerns the gene TP53 and hepatocellular carcinoma.